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Abstract 
In chemical glycosylation reactions, a glycosyl donor couple with glycosyl acceptor through 
glycosidic linkage. Most of the products end up with mixture due to the formation of stereogenic 
center at anomeric carbon. Activation with suitable Lewis acid and introduction of the non-
participating protecting group on donor and acceptor results in a selective product. Herein, we used 
suitably protected donor and acceptor which produced orthogonally protected building block with α-
selectivity. We used also donor for the synthesis of modified phosphoribosylated amino acid. The 
formation of glycoside products can be used to synthesize complex biologically important organic 
molecules. 
 
Introduction 
The glycosylations are considered to play a vital role in a wide range of regulatory processes 
and glycoside products can be used to synthesize complex organic molecules which are of vital 
importance for the maintenance of diverse cellular functions.[1] Poly-adenosine diphosphate (ADP) 
ribosylation is one of the complex polymeric post-translational modification (PTM) that occur at 
various functional groups in amino acid side chains (Fig. 1).[2-5] The carbohydrates occur as 
polysaccharides, glycoconjugates or glycosides and  in their chemical synthesis, the main challenge is 
to build glycosidic linkages between the monomeric units with appropriate orientation and most of 
glycosylations give a mixture of the product.[6-9] The improvement of new methodologies for chemical 
glycosylation has emerged as an active area of research. Several types of new glycosyl donors for 
glycosylation reactions have been synthesized and applied. Diverse activation protocols have been 
established for the successful assembly of oligosaccharides from protected building 
blocks. Herein, we describe the glycosylation reactions resulted in synthesis of a ribosylated-amino 
acid 8, and adenosine 9. The glycosylation of adenosine gave an orthogonal bifunctional building 
block 9, which may be used for future coupling reactions with amino acids and in the synthesis 
of PTMs (Fig. 1). 
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Figure 1. Post-translational protein modification (PTM): e.g; Poly-ADP-ribose polymer attached to protein. 
We developed a synthetic route for the synthesis of benzyl protected phosphorylated 
ribofuranosyl N-phenyltrifluoroacetimidate 1 (Scheme 1) which was used in two representative  
glycosylation reactions; in synthesis of compounds 8 and 9. The synthesis of 1 involved the following 
synthetic steps: i) synthesis of methyl D-ribofuranoside 3 according to the reported procedure,[10] ii) 
phosphorylation of methyl D-ribofuranoside 3 through using P-amidite chemistry,[11] iii) benzylation 
of phosphorylated methyl D-ribofuranoside 4 to protect the secondary hydroxyl  groups,[6,7] iv) 
deprotection of the anomeric methoxy to hydroxyl group via hydrolysis to give 6, v) and finally 
introduction of the (N-phenyl)-2,2,2-trifluoroacetimido group on the anomeric hydroxy function 
group (Scheme 1).[8,9]  
 
Scheme 1. Synthesis of benzyl-phosphorylated ribofuranosyl N-phenyltrifluoroacetimidate 1. 
After the synthesis of donor 1, 3,5-O-di-tert-butylsilyl protected N-benzoyl adenosine 2 was 
synthesized in order to obtain a bifunctional building block 9. The synthesis of compound 2 was 
achieved according to a reported procedure.[12-14] However, The phosphorylated donor 1 was also used 
for the preparation of ribosylated amino acid 8 (Scheme 3). [15,16]  After the C-terminal deprotection of 
8 by using 20 mol% Pd(PPh3)4 and excess dimedone in THF, give building block 11 with a terminal 
phosphoribose moiety which can be used in future for coupling reactions and phosphorylations with 
precise control over the number of modifications.[17,18] 
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Scheme 2. Synthesis of orthogonal bifunctional building blocks 9, 10. 
 
Scheme 3. Synthesis of ribosyl amino acid derivatives 8, 11. 
Generally, the synthesis of nucleosides with O-glycosylation on 2′-OH are considered 
difficult reactions., causing the formation of sideproducts in the reaction mixture and decreasing the 
yield of the desired O-glycosylated nucleoside.[6-8] Some reports containing examples of the 
glycolysation of nucleosides with pyranosyl moieties, shimofuridin,[19,20] and adenophostin,[21-23] 
possessing 2′-O-β-fucopyranosyl and  3′-O-α-glucopyranosyl respectively have been reported. A 
number of synthetic nucleosides with O-β-linked furanosyl groups are also reported.[24-26] However, 
very few examples have been reported for the synthesis of 2′-O-α-D-ribofuranosyladenosine which 
have 2′-O-α-ribosylated adenosine.[15-18,27] In one example, the synthesis of 2′-O-α-D-
ribofuranosyladenosine involved selective trans-coupling of arabinofuranose to adenosine, then 
subsequent attachment of the 2′-O-acyl group, proceeding by inversion of the stereochemistry at the 
2-position of the arabinofuranose via an oxidation reduction sequence. To significantly improve 
previous procedures, we utilized the building block, di-tert-butylsilyl-protected adenosine nucleoside 
(2, Scheme 2).[12-16] Using this block, and benzyl-phospho-ribofuranosyl N-phenyltrifluoroacetimidate 
as a donor 1, it was possible to synthesize a α-riboside in excellent yield with orthogonal protective 
groups (Scheme 2). Filippov et al. reported similar kind of phosphorylated orthogonal building block 
in multiple steps synthesis (8-10 steps) using protecting and deprotecting chemistry and finished with 
laborious work up to provide free primary OH that was further functionalized with phosphoramidite 
group. [16] We synthesized phosphorylated orthogonal building block with free primary OH in two 
steps which possibly be functionalized with phosphoramidite group. 
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The imidate 1 activated with TMSOTf (Lewis acid) in the presence of acceptor 2 resulted in 
the formation of 9 with excellent α-selectivity in 85% yield (Scheme 2). The stereochemistry was 
assigned according to the literature.[28-30] The exocyclic amine of acceptor was dibenzoylated to avoid 
the side reaction. However, non-participating benzyl protection and (N-phenyl)-2,2,2-
trifluoroacetimido group on the ribofuranosyl donor predominantly renders the α-product in 
glycosylation reactions. We deprotected silyl group of orthogonal bifunctional building block 9 to get 
compound 10 in 79% yield. However, the complete deprotection of 9 can be attempt by following the 
given literature.[6,7] We also synthesized phosphoribosylated amino acid 8 in 73% yield (Scheme 3) by 
using imidate 1 and glutamic acid 7. For this glycosylation reaction, also the TMSOTf used as an 
activator. The compounds 10 and 11 can possibly be used for extension of phosphate and peptide 
chain for PTMs.[17,18]   
Conclusions 
We successfully synthesized ribosyl donor 1, phosphoribosylated amino acid derivatives 8, 11 and 
orthogonal bifunctional building blocks 9 and 10 which may provide an opportunity for the 
preparation of synthetic material for PTMs in a defined way. 
Experimental Section 
 General 
All chemicals were purchased from Sigma-Aldrich and Merck. Reactions were carried out under N2 or 
Ar. Solvents for reactions were distilled prior to their use. Evaporation of the solvents in vacuo was 
done with the rotary evaporator. Merck silica gel 60 (40 – 63 μm) was used for column 
chromatography. Merck thin layer chromatography plates silica gel 60 on aluminum were used for the 
spots visualizing by UV light. KMnO4 and p-anisaldehyde solutions were used for staining. For 1H-
NMR spectra; Bruker AV-300 (300 MHz), Bruker AV-400 (400 MHz) and Bruker AV-500 (500 MHz) 
were used. For 13C-NMR spectra; Bruker AV-300 (75.5 MHz), Bruker AV-400 (100 MHz) and Bruker 
AV-500 (125 MHz) were used. For 31P-NMR spectra; Bruker AV-300 (75.5 MHz) or Bruker AV-400 
(161 MHz) were used.  
Experimental 
Synthesis of 4. 4,5-Dicyanoimidazole (DCI, 1.95 g, 16 mmol) was added to a soln. of 3 (2.464 g, 15 
mmol) and (BnO)2PNiPr2 (technical grade, 90%, 5.76 g, 15 mmol) in DMF (15 mL) at –10°C. The 
soln. was stirred at –10°C. After 5 h mCPBA (70%, 4.04 g, 18 mmol) was added in small portions and 
after stirring for another 0.5 h at 25°C the reaction soln was diluted with Et2O and washed with H2O 
(3 x 30 mL). The aq. layer was extracted with Et2O (3 x 30 mL) and the combined org. layer were 
dried with MgSO4. Evaporation of solvent in vacuo delivered colorless solid as crude product of 4 
(7.37 g). Filtration over silica gel (CH2Cl2/MeOH 10:0 to 10:1) delivered colorless oil of 4 (3.61 g, 9 
mmol, 60%). 1H-NMR (400 MHz, CDCl3): 7.41 – 7.30 (m, 2 x Ph), 5.05 – 5.03 (m, 2 x OCH2Ph), 
4.67 (s, 1 H), 4.17 – 4.09 (m, 1 H), 3.99 – 3.88 (m, 3 H), 3.74 (d, J = 4.1, C1H), 3.19 (s, CH3), 2.89 (s, 
C3OH), 2.73 (broad s, C2OH). 13C-NMR (100 MHz, DMSO): 136.1, 136.0 (2s, 2 x OCH2Ph), 128.5, 
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128.3, 127.8 (10d, 2 x OCH2Ph), 108.3 (d, C1), 80.6 (d, C4), 74.0 (d, C2), 70.6 (d, C3), 3 x 68.5 (3t, 
C5, 2 x CH2Ph), 54.3 (q, CH3). 31P-NMR (161 MHz, CDCl3): –3.44 (quin). HR-ESI-MS (MeOH + 
NaOH): 447.11782 (C20H25NaO8P+, [M + Na]+, calc. 447.11793, Δm = 0.2 ppm). 
Synthesis of 5. NaH (60%, 0.64 g, 16 mmol) was added in small portions to a soln. of 4 (3.08 g, 7 
mmol) in dry DMF (25 mL) at –10°C. Benzyl bromide (2.76 g, 16 mmol) was added after 5 min to 
the pale yellow and bubbling suspension. The reaction mixture was stirred for 1.5 h at -10°C before it 
was allowed to warm to 0°C. It was stirred for another 3.5 h at 0°C before TLC showed full 
consumption of 4 and the reaction was quenched by addition of H2O (30 mL). The mixture was 
extracted with Et2O (3 x 150 mL) and the collected org. layers were dried with MgSO4. Evaporation 
of the solvent in vacuo delivered turbid pale yellow liquid as crude product of 5 (4.98 g). Purification 
by column chromatography (pentane/Et2O 1:1 to 1:3) delivered colorless oil of 5 (3.36 g, 5 mmol, 56 
%). 1H-NMR (400 MHz, CDCl3): 7.33 – 7.10 (m, 4 x Ph), 5.08 (s, 1 H), 2 x 4.93 (2d, J = 7.8, 2 x 
POCH2Ph), 4.79 (s, 1 H), 4.52 (q, J = 12, 1 H), 4.42 (d, J = 11.7, 1 H), 4.32 (d, J = 11.7, 1 H), 4.27 – 
4.16 (m, 1 H), 4.10 – 3.89 (m, C5H2, there in 3.99 – 3.96 (t-like m, C4H)), 3.73 (d, J = 4.5, C1H), 
3.18 (s, CH3). 13C-NMR (100 MHz, CDCl3): 137.8 (4s, Ph), 128.7, 3 x 128.6, 128.3, 128.1, 2 x 128.0 
(20d, 4 x Ph), 106.4 (d, C1), 79.8 (d, C4), 79.6 (d, C2), 78.1 (d, C3), 72.7, 72.5 (2t, 2 x COCH2Ph), 2 
x 69.4 (2t, 2 x POCH2Ph), 68.1 (t, C5), 55.1 (s, CH3). 31P-NMR (161 MHz, CDCl3): –1.06 (quin). 
HR-ESI-MS (MeOH + NaOH): 627.21201 (C34H37NaO8P+, [M + Na]+, calc. 627.21183, Δm = 0.3 
ppm). 
Synthesis of 6. 5.5 ml HCl was added to a solution of 5 (1.80 g, 3 mmol) in CH3CN (55 mL). The 
solution was stirred at room temperature for 2 h. Then, ethyl acetate (excess) and brine solution were 
added to quench reaction. Organic layer was separated and dried over Na2SO4 and concentrated in 
vacuo. The desired alcohol was purified by Silica gel column chromatography (CH2Cl2/EtOAC (50:1 
to 50:10)) (1.20g, mmol, 60% yield) as a transparent oil.1H-NMR (400 MHz, DMSO): 7.37 – 7.05 (m, 
20 H), 5.05 – 4.85 (m, 4 H), 4.66 – 4.34 (m, 4 H), 4.25 – 3.96 (m, 4 H), 3.91 – 3.68 (m, 3 H). 13C-
NMR (100 MHz, CDCl3) δ: 137.75, 135.62, 135.94, 135.90, 135.87, 135.83, 128.59, 128.46, 127.94 
(arom), 106.31, 79.73, 77.98, 72.56, 69.34, 67.98. 31P-NMR (161 MHz, DMSO): –0.71 (quin). ESI-
MS (MeOH + NaOH): 613.2 (C35H35NaO8P+, [M + Na]+, calc. 613.2). 
Synthesis of 1. Compound 6 (120 mg, 0.2 mmol) was dissolved in acetone (3 mL) and 100 μL water. 
Cs2CO3 (71 mg, 0.2 mmol, 1.1 eq.) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride ClC(=NPh)CF3 
(30 μL, 0.2 eq.) were added and the reaction mixture was stirred at room temperature for 7 hours. 
After filtration over celite, the solvents were removed and the residue was purified using silica gel 
column chromatography (CH2Cl2/EtOAc (10:1) to afford the title compound as a colourless oil (107 
mg, 70%).1H-NMR (400 MHz, CDCl3) δ: 7.52 – 7.16  (m, 22H, arom), 7.02 (m, 1H, arom), 6.71 (dd, 
J = 16.7, 7.5 Hz, 2H, arom), 6.20 (s, 1H, H1),  4.95 – 4.91 (m, 4H, CH2 Bn), 4.63 – 4.60 (m, 1H, H4’) 
4.54 – 4.33 (m, 4H, CH2 Bn), 4.15 – 4.11 (m, 1H, H3’), 4.08 – 4.01 (m, 1H, H2’), 3.96 (AB,  J = 
11.3, 4.3 Hz, 1H, H5’), 3.85 (AB, J = 11.3, 4.0 Hz, 1H, H5’). 13C-NMR (100 MHz, CDCl3) δ: 142.55, 
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136.17,134.79, 134.67, 128.24, 127.72, 127.51,127.11, 127.01, 126.91, 126.59, 125.15, 123.31, 
119.57, 118.46, 101.11 (C1), 80.06 (C4), 77.25 (C2), 76.32 (C3), 71.77, 71.32, 68.38 (CH2 Bn), 
65.73 (C5). 31P-NMR (161 MHz, CDCl3): –1.28. ESI-MS (MeOH + NaI): 762.8 (C41H39 F3NO8P+, [M 
+ H]+, calc. 761.7). 
Synthesis of 9. The trifluoroacetimidate donor dissolved   (1, 152mg, 0.2 mmol) in dry CHCl3 (1ml), 
was added slowly at 0 OC to the solution of acceptor 2 (100mg, 0.16 mmol) and Trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) (9ul, 0.2 eq.) in dry CHCl3 (1 ml) containing freshly activated 4 
Å molecular sieves, and then solution was stirred under Nitrogen atmosphere for 3h at 0 OC and 
quenched by the addition of triethylamine (TEA, 200 ul). The reaction mixture was concentrated in 
vacuo. After evaporation of the solvent the crude material was purified using silica gel column 
chromatography (hexane/EtOAc (3:2) as white foam (202 mg, 85% yield). 1H NMR (500 MHz, 
CDCl3) δ 8.58 (s, 1H, C2), 7.94 (s, 1H, C8), 7.88-7.25 (m, 30H, Arom. Bz , Bn), 6.06 (s, 1H, H1”), 
5.40 (d, J = 4.0 Hz, 1H, H1’), 4.71 – 4.49 (m, 10H, CH2 Bn’s, C3”, C2” ), 4.35-3.41 (m, 1H, C4”, 
C5”, C2’, C3’, C5’), 1.28 – 0.97 (m, 18H, t-butyl.). 13C NMR (125 MHz, CDCl3) δ 170.10, 149.40, 
142.87, 131.86, 131.06, 127.47, 126.78, 126.53, 126.37, 126.30, 126.22, 126.02, 125.89, 125.85, 
125.78, 90.47 (C1’), 86.31 (C1”), 71.81, 71.05, 67.21, 60.89, 34.10, 31.40. 31P-NMR (161 MHz, 
CDCl3): –1.17. ESI-MS (MeOH + NaI): 1189.5 (C65H71N5O13PSi+, [M + H]+, calc. 1188.4 
Synthesis of 10. Compound 9 (120 mg, 0.1mmol) was dissolved in THF (5 mL). Treatment with 
TBAF (52.3mg, 2 eq.) at room temperature for one hour, concentration (Reaction was monitored by 
TLC, CH2Cl2: Methanol, 5:0.5) and purification using column chromatography (CH2Cl2: EtOAc, 3:4) 
afforded the title compound as a colourless syrup 10 (84 mg, 79% yield). 1H NMR (500 MHz, CDCl3) 
δ 8.51 (s, 1H, C2), 8.01 (s, 1H, C8), 7.94-7.14 (m, 30H, Arom. Bz , Bn), 6.36 (d, J = 7.4 Hz 1H, H1”), 
5.91 (s, 1H, C5” OH)  5.48 (d, J = 7.2 Hz, 1H, H1’), 5.19 4.71 – 4.49 (m, 4H, P-O-CH2 Bn’s) 4.91 – 
4.80 (m, 5H, CH2 Bn’s, C4”), 4.75-4.32 (m, 5H, C2”, C3’, C5”, C4’) 4.28 (s, 1H, C3” OH), 4.05-3.78 
(m, 4H, C3”, C2’, C5’). 13C NMR (125 MHz, CDCl3) δ 173.10, 152.24, 145.58, 137.47, 136.38, 
134.62, 133.91, 130.09, 129.42, 129.36, 129.26, 129.18, 128.99, 128.99, 128.85, 128.64, 128.45, 
126.11, 102.09 (C1’), 100.11 (C1”), 71.32, 70.05, 66.29, 63.40, 56.10. 31P-NMR (161 MHz, CDCl3): 
–1.24. ESI-MS (MeOH + NaI): 1048.35 (C57H55N5O13P+, [M + H]+, calc. 1048.35 
Synthesis of 8. The trifluoroacetimidate donor dissolved (1, 38mg, 0.05 mmol) in dry CHCl3 (0.5ml), 
was added slowly at 0 OC to the solution of glutamic acid 7 (20mg, 0.05 mmol) and Trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) (2.5ul, 0.05 eq.) in dry CHCl3 (0.5 ml) containing freshly 
activated 4 Å molecular sieves, and then solution was stirred under Nitrogen atmosphere for 6h at 0 
OC and quenched by the addition of triethylamine (TEA, 200 ul). The reaction mixture was 
concentrated in vacuo. After evaporation of the solvent the crude material was purified using silica gel 
column chromatography (CH2Cl2/EtOAc (5:1) as white syrup (35 mg, 73% yield). 1H-NMR (500 
MHz, CDCl3) δ: 7.67 – 7.17 (m, 29H, arom), 6.16 (s, 1H, H1’-α), 5.78 –5.75 (m, 1H, -CH=),  5.78 –
5.75 (m, 1H, -CH=),  5.40-5.39 (d, 1H, =CH-), 5.23-3.22 (m, 19H, CH2 Bn, -CH2-, O-CH2-, -,-CH-, 
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H3’, H4’, H5’ ), 2.40-1.92 , (m, 4H, -CH2-CH2-). 13C-NMR (125 MHz, CDCl3) δ: 172.51, 171.28, 
156.93, 144.01, 142.89, 138.14, 137.39, 136.15, 135.98, 132.07, 129.27-127.70 (arom.), 101.30, 
100.11 (C1’), 99.35, 98.74, 95.57, 75.41, 73.63, 73.33, 73.08, 70.08, 66.69, 48.54, 47.77, 31.05, 
27.22. 31P-NMR (161 MHz, CDCl3): –0.97. ESI-MS (MeOH + NaI): 1004.35 (C57H55N5O13P+, [M + 
Na]+, calc. 1004.34) 
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